Immune & Inflammatory Rheumatic Diseases (inc. Arthritis) Evaluations
To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.
Sign in | Free Trial | Subscribe | Recommend to Library
New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.
SECTION HEADS
Section Topics
- » Ankylosing spondylitis
- » Autoantibodies
- » Autoimmunity in general
- » Autoinflammatory syndromes
- » Biologic therapies
- » Crystal induced arthropathies
- » Gout (arthritis urica)
- » Infectious arthritis
- » Inflammatory bowel disease & celiac disease
- » Inflammatory myopathies
- » Juvenile idiopathic arthritis
- » Pathogenesis of inflammation
- » Polymyalgia rheumatica
- » Psoriatic arthritis
- » Reactive arthritis
- » Rheumatoid arthritis
- » Scleroderma
- » Sjogrens syndrome
- » Systemic lupus erythematosus (including anti-phospholipid antibody syndrome)
- » Vasculitis
LATEST EVALUATION
Rene Toes and Andreea Ioan-Facsinay, Leiden University Medical Center, Netherlands. F1000 Rheumatology & Clinical Immunology
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
1 Evaluation, most recent by
Paul Peloso, Merck & Co., Inc., USA. F1000 Rheumatology & Clinical Immunology
- Clinical Trial
- Controversial
- Confirmation
INDIVIDUALS
Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.
Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.
RECOMMENDATIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
LIBRARIANS & INFORMATION MANAGERS
Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.
FREE ACCESS
Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
